Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Recruiting · NCT07443397 · Registry updated 2026-03-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. | Whole-Brain Radiotherapy | Recruiting | Phase 3 | 2026-03-02 | NCT07443397 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College | Beijing | China | 1 |